KEY POINTS
- This PRISMA-ScR scoping review screened 5,732 publications and included 137 clinical studies evaluating cardiac effects after conventional thoracic radiotherapy. SABR studies were excluded because their dose–effect relationships were considered biologically distinct.
- Myocardial damage and ventricular dysfunction were repeatedly associated with local dose to myocardial and ventricular segments, while several studies also implicated coronary arteries, particularly the left anterior descending artery.
- Coronary artery disease showed associations with heart, ventricular, and individual coronary artery dose across multiple studies. The available evidence suggests that if a coronary dose threshold exists, it is likely low, but no reliable threshold can yet be defined.
- Pericardial complications showed one of the clearest structure-specific signals: most studies found stronger associations with pericardial dose than whole-heart dose, supporting the pericardium itself as the relevant organ at risk for this endpoint.
- Arrhythmias appear similarly anatomy-specific. Reported associations involved atrial structures, pulmonary veins, the sinoatrial node, and coronary arteries, consistent with different arrhythmia phenotypes arising from different anatomical substrates.
- Lung irradiation may also contribute to cardiac injury. Clinical associations between lung dose and myocardial damage or valvular disease were reported, but heart and lung doses are highly correlated, so an independent pulmonary contribution remains uncertain.
- Evidence directly proving that radiation-induced cardiac toxicity reduces survival was limited and inconsistent. Associations between cardiac or pulmonary dose and poorer survival were more common, but these remain indirect evidence because dose also correlates with tumor burden, target size, pulmonary toxicity, lymphopenia, and comorbidity.
CLINICAL TAKEAWAY
Mean heart dose is increasingly inadequate as the only cardiac planning metric: different cardiac toxicities appear to map to different anatomical structures. The review supports greater attention to cardiac substructure dosimetry, but current evidence is too heterogeneous to justify robust universal dose constraints for most individual structures.